EORTC’s presence at ESMO 2023
17 Oct 2023
New findings and upcoming EORTC trials in lung, head and neck, breast and rare cancers will be presented at ESMO 2023 in Madrid, highlighting EORTC’s commitment to innovative non-commercial cancer research. Seven abstracts have been accepted, with one of them being an oral presentation. Additionally, EORTC’s Scientific Director, Jan Bogaerts, will delve into the realm of pragmatic trials during a special session on Sunday, 22 October 2023. For a comprehensive overview of EORTC’s activities at ESMO, please refer to the table below.
EORTC presentations:
Presentation title | Presentation details |
---|---|
Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI): Two years update Madeline Pe, Belgium |
Friday, 20 October 2023 at 2:00 PM Room: Ávila Auditorium – NCC |
Pragmatic Trials Jan Bogaerts, Belgium |
Sunday, 22 October 2023 at 10:15 AM Room: León Auditorium – Hall 7 |
EORTC abstracts accepted at ESMO:
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023